Curevac N.V. was incorporated under the laws of the Netherlands on April 7, 2020. The company is a global clinical-stage biopharmaceutical company developing novel translational drugs based on messenger ribonucleic acid that have the potential to improve people's lives. 

BioNTech SE has completed its exchange offer to acquire CureVac, a clinical-stage biotechnology company. CureVac will be delisted from the Frankfurt Stock Exchange and its shares will be converted into BioNTech shares. The deal is expected to strengthen BioNTech's position in the mRNA-based therapy market.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1bc71dcced1ce002.png" alt="BioNTech Completes CureVac Exchange Offer">

Curevac

BioNTech

BioNTech Completes CureVac Exchange Offer

BioNTech has completed its exchange offer to acquire CureVac, with approximately 86.75% of CureVac shares tendered. BioNTech expects to complete the compulsory acquisition of remaining CureVac shares in January 2026. CureVac will continue to operate under its existing processes, while BioNTech will analyze the future organizational and portfolio setup. The acquisition complements BioNTech's capabilities in mRNA design, delivery, and manufacturing.

BioNTech completes acquisition of CureVac with 86.75% of shares tendered.

BioNTech has acquired CureVac N.V. in a deal that complements its capabilities in mRNA design, delivery formulations, and manufacturing. Approximately 86.75% of CureVac shares were tendered, with BioNTech expecting to complete the compulsory acquisition of the remaining shares in January 2026. CureVac will continue to operate under its existing processes, while BioNTech will analyze future organizational and portfolio setup. The acquisition strengthens BioNTech's position in the mRNA field and supports its oncology strategy.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1bc71384a06f0002.png" alt="BioNTech Completes Acquisition of CureVac, Strengthening Its Position in the mRNA Field">

BioNTech Completes Acquisition of CureVac, Strengthening Its Position in the mRNA Field

CureVac NV has been dropped from the S&P Global BMI Index. The company is a clinical-stage biopharmaceutical firm based in Germany, developing transformative medicines based on messenger ribonucleic acid (mRNA). CureVac's mRNA platform optimizes mRNA constructs to induce a desired immune response or replace defective proteins. The company's product portfolio includes clinical and preclinical candidates across various disease indications, including prophylactic vaccines, oncology, and molecular therapy.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1bc696a0085ce001.png" alt="CureVac N.V. Removed from S&amp;P Global BMI Index Amid Biopharmaceutical Shifts">

CureVac N.V. Removed from S&P Global BMI Index Amid Biopharmaceutical Shifts

BioNTech maintains its "Strong Buy" rating after successful part 1 results of its next-gen anti-CTLA-4 Gotistobart. The company's acquisition of CureVac brings a complementary method to target cancer, expanding its portfolio and increasing its potential in the cancer treatment market.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1bbc31b99ef6c001.png" alt="BioNTech Maintains &quot;Strong Buy&quot; Rating After Positive Part 1 Results for Next-Gen Anti-CTLA-4 Gotistobart Trial">

CVAC News